ID: ALA1935574

Max Phase: Preclinical

Molecular Formula: C16H17N5O

Molecular Weight: 295.35

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1nc(N2CCNCC2)c2ccc(-c3ccco3)cc2n1

Standard InChI:  InChI=1S/C16H17N5O/c17-16-19-13-10-11(14-2-1-9-22-14)3-4-12(13)15(20-16)21-7-5-18-6-8-21/h1-4,9-10,18H,5-8H2,(H2,17,19,20)

Standard InChI Key:  UBEJREHBDACTGD-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 295.35

Molecular Weight (Monoisotopic): 295.1433

AlogP: 1.88

#Rotatable Bonds: 2

Polar Surface Area: 80.21

Molecular Species: BASE

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.77

CX LogP: 2.15

CX LogD: 0.74

Aromatic Rings: 3

Heavy Atoms: 22

QED Weighted: 0.75

Np Likeness Score: -1.25

References

1. Smits RA, Lim HD, van der Meer T, Kuhne S, Bessembinder K, Zuiderveld OP, Wijtmans M, de Esch IJ, Leurs R..  (2012)  Ligand based design of novel histamine H₄ receptor antagonists; fragment optimization and analysis of binding kinetics.,  22  (1): [PMID:22153663] [10.1016/j.bmcl.2011.10.104]

2. Andaloussi M, Lim HD, van der Meer T, Sijm M, Poulie CB, de Esch IJ, Leurs R, Smits RA..  (2013)  A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: comparison of hERG binding and target residence time with PF-3893787.,  23  (9): [PMID:23558237] [10.1016/j.bmcl.2013.02.091]

Source

Source(1):

• Scientific Literature